Apollo Endosurgery base_Aktie

Apollo Endosurgery base_Marktkapitalisierung 2025

Apollo Endosurgery base_Marktkapitalisierung

406,50 number_format_mio USD

components_StockPageHeader__3

APEN

components_StockPageHeader__4

US03767D1081

components_StockPageHeader__5

A2DJ26

pages_kennzahlen_[key]_[isin]__30

pages_kennzahlen_[key]_[isin]__70

components_DataTable__24components_DataTable_25
2022242,24
2021203,98
202049,66
201970,64
2018124,78
2017103,94
20165,60
201521,47
20149,41
20130,86
20120,83
20110,87
20100,53
20090,73
20080,93
20070,84

Apollo Endosurgery Aktienanalyse

pages_kennzahlen_[key]_[isin]__1

Apollo Endosurgery Inc is a medical technology company based in Austin, Texas that specializes in minimally invasive surgical technologies and products. It was founded in 2005 and has since become one of the leading providers of endoscopic instruments and systems. The business model of Apollo Endosurgery is based on the development and marketing of innovative products for minimally invasive surgery. The company focuses on three main areas: bariatric surgery, gastrointestinal surgery, and endoscopic surgery. The goal is to provide patients with minimally invasive solutions that are less invasive, safer, and more effective than traditional surgical methods. In the field of bariatric surgery, Apollo Endosurgery offers a wide range of products for the treatment of obese patients. This includes the bioabsorbable Orbera gastric balloon system, which provides a non-surgical alternative for weight reduction. It is introduced endoscopically into the stomach and can reduce the volume of the stomach, resulting in a faster feeling of satiety. The system needs to be removed after six months, but studies have shown that it can lead to significant weight loss. In the gastrointestinal surgery sector, Apollo Endosurgery offers the OverStitch system for endoscopic sutures. This system allows for the safe and easy performance of sutures in hard-to-reach areas of the GI tract without the need for open surgery. The system can be used for a variety of applications, including the treatment of fistulas and sealing leaks in the esophagus and intestine. Apollo Endosurgery's endoscopic surgery division focuses on the development of instruments and systems for endoscopic procedures. This includes the OverStitch system, as well as the Flex-Endoflex system for endoscopic procedures in the biliary system. These products enable safer and more effective procedures. Overall, Apollo Endosurgery has developed a wide range of products for minimally invasive surgery, offering doctors and patients a variety of treatment options. The company has also evolved through acquisitions, such as the acquisition of the biopolymer-based Orbera system by Apollo Endosurgery Inc. The company has a strong international presence, operating in Europe, Asia, and the USA, and has numerous partners in these regions. It has established close relationships with key clinics and physicians and is actively involved in researching and developing new technologies for minimally invasive surgery. In conclusion, Apollo Endosurgery Inc is a leading medical technology company focused on the development of innovative products for minimally invasive surgery. The company offers a wide range of products for bariatric, gastrointestinal, and endoscopic surgery and has strong relationships with key clinics and physicians. Apollo Endosurgery has a strong international presence and consistently works on researching and developing new technologies to provide minimally invasive solutions for patients worldwide. Apollo Endosurgery ist eines der beliebtesten Unternehmen auf Eulerpool.com.

pages_kennzahlen_[key]_[isin]__85

pages_kennzahlen_[key]_[isin]__77

pages_dividenden_[isin]_index__2

components_kpi_MCAPFaqs_0

components_kpi_MCAPFaqs_1

components_kpi_MCAPFaqs_2

components_kpi_MCAPFaqs_3

components_kpi_MCAPFaqs_4

components_kpi_MCAPFaqs_5

components_kpi_MCAPFaqs_6

components_kpi_MCAPFaqs_7

components_kpi_MCAPFaqs_8

components_kpi_MCAPFaqs_9

components_kpi_MCAPFaqs_10

components_kpi_MCAPFaqs_11

components_kpi_MCAPFaqs_12

components_kpi_MCAPFaqs_13

components_kpi_MCAPFaqs_14

components_kpi_MCAPFaqs_15

components_kpi_MCAPFaqs_16

components_kpi_MCAPFaqs_17

pages_aktie_[isin]_[key]_index_0

pages_aktie_[isin]_[key]_index_1

pages_aktie_[isin]_[key]_index_2

pages_aktie_[isin]_[key]_index_3

pages_aktie_[isin]_[key]_index_4

pages_aktie_[isin]_[key]_index_5

pages_aktie_[isin]_[key]_index_6

pages_aktie_[isin]_[key]_index_7

pages_aktie_[isin]_[key]_index_8

pages_aktie_[isin]_[key]_index_9

pages_aktie_[isin]_[key]_index_10

pages_aktie_[isin]_[key]_index_14

Wann musste ich die Aktien von Apollo Endosurgery kaufen, um die vorherige Dividende zu erhalten?

pages_aktie_[isin]_[key]_index_15

pages_aktie_[isin]_[key]_index_16

pages_aktie_[isin]_[key]_index_18

pages_aktie_[isin]_[key]_index_19

pages_aktie_[isin]_[key]_index_20

pages_aktie_[isin]_[key]_index_21

pages_aktie_[isin]_[key]_index_22

components_kpi_Savingsplan_0